There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter 2024 Earnings Conference Call. My name is Tawanda, and I will be your ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent ... Ironically, the best way to mitigate these risks ...

To play this video you need to enable JavaScript. Watch Bailey perform her song Cobalt Blue by the sea. Bailey talks about living in St Ives and becoming a musician. What is the meaning of the ...

Last year ended with warnings about malicious websites parting holiday shoppers with their hard earned cash, and 2025 has started the same. This time it’s more specific than the unprecedented fraud we ...

The CEO discussed the success of Dupixent and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and setting a milestone for Sanofi.

The sum-of-the-parts way and the platform way. Regeneron has 11 approved drugs but two comprise most of the cash flows. The two are Eylea and Dupixent.

We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other ...